Campo E, Jaffe ES, Cook JR, Quintanilla-Martinez L, Swerdlow SH, Anderson KC, et al. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood. 2022;140:1229–53. https://doi.org/10.1182/blood.2022019016.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Darlix A, Zouaoui S, Rigau V, Bessaoud F, Figarella-Branger D, Mathieu-Daudé H, et al. Epidemiology for primary brain tumors: a nationwide population-based study. J Neurooncol. 2017;131:525–46. https://doi.org/10.1007/s11060-016-2340-5.

Article  CAS  PubMed  Google Scholar 

Calimeri T, Steffanoni S, Gagliardi F, Chiara A, Ferreri AJM. How we treat primary central nervous system lymphoma. ESMO Open. 2021;6:100213 https://doi.org/10.1016/j.esmoop.2021.100213.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang L, Zhang Q. A systematic review of primary central nervous system lymphoma. Holist Integr Oncol. 2024;3:19 https://doi.org/10.1007/s44178-024-00086-9.

Article  Google Scholar 

Scordo M, Wang TP, Ahn KW, Chen Y, Ahmed S, Awan FT, et al. Outcomes associated with thiotepa-based conditioning in patients with primary central nervous system lymphoma after autologous hematopoietic cell transplant. JAMA Oncol. 2021;7:993–1003. https://doi.org/10.1001/jamaoncol.2021.1074.

Article  PubMed  PubMed Central  Google Scholar 

Houillier C, Taillandier L, Dureau S, Lamy T, Laadhari M, Chinot O, et al. Radiotherapy or autologous stem-cell transplantation for primary CNS lymphoma in patients 60 years of age and younger: results of the intergroup ANOCEF-GOELAMS randomized phase II PRECIS study. J Clin Oncol. 2019;37:823–33. https://ascopubs.org/doi/abs/10.1200/JCO.18.00306.

Article  CAS  PubMed  Google Scholar 

Ferreri AJM, Illerhaus G, Doorduijn JK, Auer DP, Bromberg JEC, Calimeri T, et al. Primary central nervous system lymphomas: EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2024;35:491–507. https://doi.org/10.1016/j.annonc.2023.11.010.

Article  Google Scholar 

Ferreri AJM, Cwynarski K, Pulczynski E, Fox CP, Schorb E, Celico C, et al. Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial. Leukemia. 2022;36:1870–8. https://doi.org/10.1038/s41375-022-01582-5.

Article  CAS  PubMed  Google Scholar 

Reiss S, Yerram P, Modelevsky L. Grommes C. RARE-51. Rituximab, methotrexate, BCNU, etoposide, and prednisone (RMBVP) for the treatment of relapsed/recurrent primary central nervous system lymphoma: a retrospective single center study. Neuro Oncol. 2019;21:vi232–vi232. https://doi.org/10.1093/neuonc/noz175.1194.

Article  PubMed Central  Google Scholar 

Morris PG, Correa DD, Yahalom J, Raizer JJ, Schiff D, Grant B, et al. Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. J Clin Oncol. 2013;31:3971–9. https://ascopubs.org/doi/abs/10.1200/JCO.2013.50.4910.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Omuro A, Correa DD, DeAngelis LM, Moskowitz CH, Matasar MJ, Kaley TJ, et al. R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. Blood. 2015;125:1403–10. https://doi.org/10.1182/blood-2014-10-604561.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Houillier C, Soussain C, Ghesquières H, Soubeyran P, Chinot O, Taillandier L, et al. Management and outcome of primary CNS lymphoma in the modern era: An LOC network study. Neurology. 2020;94:e1027–39. https://doi.org/10.1212/WNL.0000000000008900.

Article  PubMed  PubMed Central  Google Scholar 

Schorb E, Isbell LK, Kerkhoff A, Mathas S, Braulke F, Egerer G, et al. High-dose chemotherapy and autologous haematopoietic stem-cell transplantation in older, fit patients with primary diffuse large B-cell CNS lymphoma (MARTA): a single-arm, phase 2 trial. Lancet Haematol. 2024;11:e196–205. https://www.sciencedirect.com/science/article/pii/S235230262300371X.

Article  CAS  PubMed  Google Scholar 

Chen C, Sun P, Cui J, Yan S, Chen H, Xia Y, et al. High-dose Methotrexate plus temozolomide with or without rituximab in patients with untreated primary central nervous system lymphoma: a retrospective study from China. Cancer Med. 2019;8:1359–67. https://doi.org/10.1002/cam4.1906.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Laack NN, Ballman KV, Brown PB, O’Neill BP. Whole-brain radiotherapy and high-dose methylprednisolone for elderly patients with primary central nervous system lymphoma: Results of North Central Cancer Treatment Group (NCCTG) 96-73-51. Int J Radiat Oncol Biol Phys. 2006;65:1429–39. https://doi.org/10.1016/j.ijrobp.2006.03.061.

Article  CAS  PubMed  Google Scholar 

Fritsch K, Kasenda B, Schorb E, Hau P, Bloehdorn J, Möhle R, et al. High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study). Leukemia. 2017;31:846–52. https://doi.org/10.1038/leu.2016.334.

Article  CAS  PubMed  Google Scholar 

Bobillo S, Khwaja J, Ferreri AJM, Cwynarski K. Prevention and management of secondary central nervous system lymphoma. Haematologica. 2023;108:673–89. https://doi.org/10.3324/haematol.2022.281457.

Article  CAS  PubMed  Google Scholar 

El-Galaly TC, Cheah CY, Bendtsen MD, Nowakowski GS, Kansara R, Savage KJ, et al. Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma. Eur J Cancer. 2018;93:57–68. https://doi.org/10.1016/j.ejca.2018.01.073.

Article  PubMed  PubMed Central  Google Scholar 

Ferreri AJM, Doorduijn JK, Re A, Cabras MG, Smith J, Ilariucci F, et al. MATRix–RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial. Lancet Haematol. 2021;8:e110–21. https://doi.org/10.1016/S2352-3026(20)30366-5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Soussain C, Suzan F, Hoang-Xuan K, Cassoux N, Levy V, Azar N, et al. Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J Clin Oncol J Am Soc. Clin Oncol. 2001;19:742–9. https://doi.org/10.1200/JCO.2001.19.3.742.

Article  CAS  Google Scholar 

Soussain C, Choquet S, Blonski M, Leclercq D, Houillier C, Rezai K, et al. Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II ‘proof-of-concept’ iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) net. Eur J Cancer. 2019;117:121–30. https://doi.org/10.1016/j.ejca.2019.05.024.

Article  CAS  PubMed  Google Scholar 

Grommes C, Gavrilovic IT, Kaley TJ, Nolan C, Omuro AMP, Wolfe J, et al. Updated results of single-agent ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL). J Clin Oncol. 2017;35:7515. https://doi.org/10.1200/JCO.2017.35.15_suppl.7515.

Article  Google Scholar 

Renaud L, Bossard JB, Carpentier B, Terriou L, Cambier N, Chanteau G, et al. Treatment with temozolomide and ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL). Eur J Haematol. 2021;107:370–3. https://doi.org/10.1111/ejh.13667.

Article  CAS  PubMed  Google Scholar 

Dhillon S. Tirabrutinib: first approval. Drugs. 2020;80:835–40. https://doi.org/10.1007/s40265-020-01318-8.

Article  CAS  PubMed  Google Scholar 

Yonezawa H, Narita Y, Nagane M, Mishima K, Terui Y, Arakawa Y, et al. Three-year follow-up analysis of phase 1/2 study on tirabrutinib in patients with relapsed or refractory primary central nervous system lymphoma. Neuro-Oncol Adv. 2024;6:1–11. https://doi.org/10.1093/noajnl/vdae037.

Article  Google Scholar 

Ghesquieres H, Chevrier M, Laadhari M, Chinot O, Choquet S, Moluçon-Chabrot C, et al. Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: A multicenter prospective “proof of concept” phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and. Ann Oncol. 2019;30:621–8. https://doi.org/10.1093/annonc/mdz032.

Article  CAS  PubMed  Google Scholar 

Nayak L, Iwamoto FM, Lacasce A, Mukundan S, Roemer MGM, Chapuy B, et al. PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma. Blood. 2017;129:3071–3. https://doi.org/10.1182/blood-2017-01-764209.